by Louise Adams | 23 May 2026 | Blog
In late 2019, 6000 researchers and clinicians gathered in Las Vegas for Obesity Week, the industry’s annual lovefest conference. Among the throng was Australian researcher Hiba Jebeile, who’d been invited by The Obesity Society (TOS) for a panel...
by Louise Adams | 1 May 2025 | Blog
I’ve emerged from the isolation tank, prepared to dive back in to our final chapter on The Lancet’s PR piece. This is Part 4 of the series: click on the links to read Part 1, Part 2, and Part 3. It’s a long read, and full of truly awful fat phobia:...
by Louise Adams | 30 Apr 2025 | Blog
Thanks for bearing with me as we trawl through the seemingly endless Lancet Commission on ‘clinical o*esity’. Click here to read Parts 1 and 2.Please be advised that the following post contains multiple meat-puns, which may be triggering to vegetarians/the...
by Louise Adams | 17 Feb 2025 | Blog
Welcome to Part 2 of our probe into the Lancet paper defining ‘clinical o*esity.’ If you haven’t read Part 1 you can do so here – it’ll make much more sense. For more than two decades I’ve been wading through the stench-swamp of o*esity research, unmasking...
by Louise Adams | 30 Jan 2025 | Blog
Since the 1990’s, the weight loss industry has been pushing to have ‘o*esity*’ classified as a disease. This is the Holy Grail for pharmaceutical companies, because disease status opens the door to government and insurance subsidies, ensuring a...
by Louise Adams | 13 Jan 2025 | Blog
I’m back with some sterling examples of how Novo Nordisk genuinely care about human health. If you haven’t already, please read Parts 1 and 2 of Risky Business, for a deep dive into Novo’s clever glow-up of their weight loss drugs as cardiovascular...
